Swiss pharmaceutical giant seeks to bolster pipeline
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
https://www.wsj.com/health/pharma/roche-to-buy-telavant-from-roivant-sciences-and-pfizer-in-7-25-bln-deal-638ccc3cRoche’s deal is the latest example of a big pharma company turning to the deal table to bolster its pipeline of autoimmune drugs.Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate Vivek Ramaswamy, and Pfizer in a deal worth more than $7 billion.
The Swiss pharmaceutical giant said Monday it would pay $7.1 billion upfront for Telavant Holdings, and make a near-term milestone payment of $150 million. Roche said the deal gives it rights to commercialize Telavant’s RVT-3101 drug candidate, which has shown promise for inflammatory-bowel disease and could have potential in other indications, in the U.S. and Japan.This copy is for your personal, non-commercial use only.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Chevron, Hess, Roivant, Textainer, Microsoft, Alphabet, and More Stock Market MoversChevron will buy Hess in all-stock deal valued at $53 billion, Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease...
Lire la suite »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Lire la suite »
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant HoldingsSwiss health care company Roche announced it would acquire Telavant Holdings Monday, in a deal worth $7.1 billion.
Lire la suite »
Roche to Buy Telavant from Roivant Sciences, Pfizer for $7.1 BillionIt will buy immunology company Telavant Holdings from Roivant Sciences and Pfizer.
Lire la suite »
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Bln -- UpdateBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...
Lire la suite »
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln DealBy Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...
Lire la suite »